ABNewswire - Press Release Distribution Service

Saturday, January 17, 2026

Eric Church 2026 Concert Tickets Discount - Apply Promo Code CITY10 Today

Feel the raw energy of Eric Church live on his 2026 Free The Machine Tour! Catch The Chief rocking the stage with hits like "Drink in My Hand," "Springsteen," & "Smoke a Little Smoke." Grab discount tickets now at CapitalCityTickets.com – use promo code CITY10 for instant savings!

Catch Eric Church live on his 2026 Free The Machine Tour! The Chief brings raw energy, hits like "Drink in My Hand," "Springsteen," "Smoke a Little Smoke," and deep cuts from Evangeline vs. The Machine. Tour kicks off Jan 22-23 in Washington, D.C. @ The Anthem (w/ Caylee Hammack), then Omaha Feb 5, Sioux Falls Feb 6, St. Paul Feb 7 & more through April!

Country rock rebel Eric Church (aka The Chief) is revving up for an epic 2026 extension of his Free The Machine Tour! Supporting his acclaimed ninth studio album Evangeline vs. The Machine, Church delivers raw, high-energy performances packed with fan favorites like “Drink in My Hand,” “Springsteen,” “Smoke a Little Smoke,” “Heart on Fire,” “Johnny,” “Hands of Time,” and more. Expect genre-defying sets, killer storytelling, and that signature Church Choir connection fans crave.

The 2026 leg kicks off January 22-23 in Washington, D.C. at The Anthem with special guest Caylee Hammack — just days away as of January 15, 2026! The tour rolls through arenas across the U.S. and Canada through April, featuring rotating openers like Ella Langley, Ashley McBryde, 49 Winchester, Stephen Wilson Jr., and Kashus Culpepper on select dates.

If you're hunting for discount Eric Church 2026 concert tickets, CapitalCityTickets.com has you covered! We offer cheap tickets below face value from all sections — upper level steals to closer floor seats — with transparent pricing, no hidden fees, fast secure delivery, and full buyer protection.

Why Buy Discount Eric Church Tickets from CapitalCityTickets.com?

Affordable Deals: Secure seats cheaper than official sites, perfect for every budget.

Exclusive Promo Code CITY10: Enter CITY10 at checkout for instant extra savings on your purchase!

Huge Inventory: All dates, sections, and last-minute options available.

Easy & Secure: Buy online in minutes — ideal for Church Choir members and new fans alike.

Trusted Source: Verified tickets with 100% guarantee.

Key Eric Church Free The Machine Tour 2026 Dates (Upcoming Highlights)

January 22-23, 2026 — Washington, D.C. @ The Anthem (w/ Caylee Hammack)

February 5, 2026 — Omaha, NE @ CHI Health Center Omaha (w/ Ella Langley)

February 6, 2026 — Sioux Falls, SD @ Denny Sanford PREMIER Center (w/ Ella Langley)

February 7, 2026 — Saint Paul, MN @ Grand Casino Arena (w/ Ella Langley)

February 12, 2026 — Toronto, ON @ Scotiabank Arena

February 13, 2026 — Buffalo, NY @ KeyBank Center

February 14, 2026 — Albany, NY @ MVP Arena (w/ Ella Langley)

And more through April, including stops in Kansas City, Tulsa, Fort Worth, Austin, Knoxville, Greensboro, Birmingham, Atlanta, Charlotte, and wrapping April 11 in Tampa, FL!

Shows promise high-octane energy, deep cuts, and that unbreakable bond with the audience. Tickets are flying fast — especially for the kickoff in D.C.!

How to Score Your Discount Tickets Today

Visit CapitalCityTickets.com and search for Eric Church.

Choose your date, city, and seats.

Apply promo code CITY10 at checkout for extra discounts.

Finish securely — tickets delivered fast!

Don't miss The Chief live on this fearless tour — it's pure country rebellion! Grab discount Eric Church 2026 concert tickets with promo code CITY10 at CapitalCityTickets.com today and save big on unforgettable nights. See you in the Choir!

Media Contact
Company Name: CapitalCityTickets.com
Contact Person: Media Relations
Email:Send Email
Phone: 1-855-514-5624
Country: United States
Website: https://www.capitalcitytickets.com/Eric-Church-Tickets

Chitas Launches His Own Record Label After a 10-Hour DJ Set in the Emirates

International DJ and music producer Chitas has officially launched his own record label, Imperium State Records, following an impressive 10-hour DJ set in the Emirates.

The extended performance marked an important milestone in his career. At the end of the set, Chitas announced the creation of Imperium State Records, a label open to all music styles and cultures, with a global and inclusive vision.

Chitas began his musical journey at the age of two. After playing trumpet in bands and orchestras in Portugal and studying classical and portuguese guitar, he moved into DJing and music production in 2018. Today, he is supported by international DJs and continues to develop a versatile artistic path.

The label’s first release, “Far Away”, is scheduled for January 23 and introduces the sound of Imperium State Records, with roots in Tropical House.

Beyond DJing and production, Chitas has also explored songwriting in different languages. Last year, he collaborated on two songs written in Arabic, further reflecting his openness to cross-cultural musical projects.

In addition to music releases, Imperium State Records will host a weekly radio show, airing every Saturday, featuring exclusive tracks, premieres and curated selections.

With the launch of Imperium State Records, Chitas takes a new step in his career, expanding his role from artist to label founder.

For more details, see:

Chitas Instagram: https://www.instagram.com/antonio_chitas

Chitas Website: https://chitas.mozello.com

Imperium State Records Instagram: https://www.instagram.com/imperiumstate_records

Imperium State Records Facebook: https://www.facebook.com/share/1CWhkz9FZ3

Imperium State Records Website: https://imperiumstaterecords.mozellosite.com

Media Contact
Company Name: CB Herald
Contact Person: Ray
Email:Send Email
Country: Portugal
Website: Cbherald.com

Woman-Owned Kitchen Brand Luxe Living Home Essentials Expands Reach Through Pop-Up Events and E-Commerce

Our customers are looking for solutions that fit into their actual lives, not fantasy kitchens they see on social media. That's why we focus on products that deliver real value, save time, and make cooking something people look forward to rather than dread.

Luxe Living Home Essentials is experiencing significant growth as consumers discover its unique combination of bestselling seasonings, quality kitchen tools, and practical cookbooks. The brand's founder, bestselling author Loreitha "Coach LL" Lacewell, has built a thriving business by addressing the real needs of busy households seeking elevated everyday cooking experiences.

The American kitchen and home goods market is witnessing the rise of a distinctive new player as Luxe Living Home Essentials continues gaining momentum with consumers across the United States. The woman-owned brand has carved out a unique niche by offering thoughtfully designed products that prioritize both form and function, a combination that has proven increasingly difficult to find in a marketplace often dominated by either bargain-basement pricing or inaccessible luxury positioning.

At the helm of this growing enterprise is Loreitha "Coach LL" Lacewell, whose journey from Amazon bestselling author to successful lifestyle entrepreneur demonstrates the power of authentic audience connection. Coach LL leveraged her established credibility and deep understanding of her readers' needs to create a product line that directly addresses the challenges facing modern home cooks. Her transition from writing about cooking to providing the actual tools and ingredients that make cooking easier represents a natural progression that her audience has embraced enthusiastically.

The Luxe Living Home Essentials collection encompasses three primary categories, each carefully developed to complement the others. The brand's bestselling seasonings, originating from the LL Kitchen Meals™ line, have become customer favorites for their balanced flavor profiles and versatility across various cuisines. These seasonings eliminate the guesswork from meal preparation, allowing home cooks to achieve consistent, delicious results without extensive recipe research or complicated ingredient lists.

Complementing the seasoning line, Luxe Living offers a curated selection of kitchen tools chosen specifically for their durability and everyday practicality. Rather than overwhelming customers with hundreds of gadget options, the brand focuses on essential items that genuinely improve cooking efficiency and outcomes. This edited approach has resonated strongly with consumers tired of cluttered kitchens filled with single-use tools that promised convenience but delivered disappointment.

The brand's cookbook offerings round out the product ecosystem by providing the inspiration and instruction that bring the tools and seasonings to life. Written with the same accessible, encouraging tone that made Coach LL a bestselling author, these cookbooks emphasize achievable techniques and realistic time commitments. Customers frequently report that the recipes become regular rotation staples rather than aspirational projects attempted once and abandoned.

Luxe Living Home Essentials has strategically built its business through a combination of robust online sales and carefully planned pop-up retail experiences, including its presence at established regional marketplaces such as the Pocono Bazaar. The e-commerce platform provides convenience and accessibility for customers across the country, while in-person pop-up events allow consumers to engage directly with the brand, experience products firsthand, and build trust through personal interaction.

The pop-up strategy also generates valuable customer feedback that informs product development and business decisions. By engaging directly with consumers in retail environments, the Luxe Living team gains insights that purely online operations might miss. This customer-centric approach ensures that new products genuinely address market needs rather than simply filling catalog space.

As an extension of the established LL Kitchen Meals™ brand, Luxe Living Home Essentials benefits from existing brand recognition and customer trust. The parent brand's reputation for quality and reliability transfers seamlessly to the expanded product line, reducing the typical barriers new brands face when entering competitive markets. Existing customers have become enthusiastic ambassadors, introducing friends and family to the brand and contributing to organic growth through genuine word-of-mouth recommendations.

The company's status as a woman-owned business adds another dimension to its appeal, particularly among consumers who prioritize supporting diverse entrepreneurs. Coach LL's success story inspires aspiring business owners while demonstrating that thoughtful product development and authentic customer engagement can build sustainable competitive advantages even in saturated markets.

CONTACT: https://luxelivinghomeessentials.com

https://www.facebook.com/llkitchenmeals

https://www.tiktok.com/@_llkitchenmeals?_r=1&_t=ZP-92OabCMai5v

https://www.instagram.com/lorelacewell/

Media Contact
Company Name: Luxe Living Home Essentials
Contact Person: John Watson
Email:Send Email
Country: United States
Website: https://luxelivinghomeessentials.com

Friday, January 16, 2026

What Next‑Gen Connectivity Means for Application Performance Expectations

Connectivity has always shaped how digital experiences feel, but next‑generation networks change the equation in a more fundamental way. The shift to 5G, edge compute, and advanced carrier infrastructure does not simply improve speed. It resets what users consider acceptable application behavior.

In earlier network generations, performance gaps were often tolerated. Delays, buffering, or inconsistent responsiveness were seen as limitations of the network. That tolerance is fading. As connectivity improves, users expect applications to respond instantly and behave consistently, regardless of location, device, or access network. This makes strategies like automated browser testing essential for ensuring applications meet these higher expectations and deliver a seamless experience. When those expectations are not met, frustration is directed at the application, not the network.

How Next‑Gen Connectivity Raises Performance Expectations

Next‑gen networks introduce capabilities that directly influence user perception. Lower latency enables real‑time interactions. Higher throughput supports richer interfaces and heavier data flows. Improved reliability reduces visible interruptions. Together, these changes shape a new baseline for application performance.

Users now assume that:

Pages should load without noticeable delay

Video and real‑time media should play without disruption

Interactive workflows should feel smooth even under load

These assumptions apply across consumer apps, enterprise tools, and browser‑based platforms. As networks improve, performance expectations increase automatically. Applications that fail to keep up appear outdated or poorly built, even if their core functionality remains unchanged.

Why Legacy Testing Approaches Miss Real Issues

Many performance testing strategies were designed for predictable environments. Tests are often executed in controlled labs, on stable connections, and with limited device variation. While useful, these methods fall short in next‑gen connectivity scenarios.

Modern networks behave differently in the real world. Performance fluctuates due to carrier routing, cell transitions, congestion, and policy enforcement. Devices interact with these networks in ways that simulations struggle to replicate. As a result, applications may pass internal tests but still degrade for real users.

This gap is especially visible in browser‑based applications accessed over mobile or hybrid networks. Without validating how applications behave under actual network conditions, teams risk releasing updates that appear stable internally but fail externally.

Why applications must be tested on real carrier networks

Telco testing focuses on validating application behavior under real carrier networks and real connectivity conditions. Instead of relying on simulated bandwidth or latency profiles, telco testing exposes how applications perform when traffic is routed through actual mobile networks.

This matters because carrier networks introduce variables that cannot be fully recreated in lab environments. Routing paths differ by operator. Network policies affect packet prioritization. Cell handoffs introduce latency spikes that do not appear in static tests. These factors directly influence how applications behave during real user sessions.

Telco testing helps teams understand:

Variations in performance across carriers and regions

Impact of handoffs between network types

Latency changes that affect APIs and user flows

In next‑gen environments, these factors directly influence user experience. Telco testing makes performance validation more aligned with how applications are actually consumed. Without it, teams risk validating performance in conditions users never encounter while missing issues that appear only on live networks.

Why Automated Browser Testing Becomes Essential

As applications evolve, so does their surface area. Browser‑based experiences must work across different engines, devices, and network conditions. Manual validation cannot keep pace with this complexity, especially when release cycles shorten and user environments diversify.

Automated browser testing enables teams to repeatedly validate user flows across browsers and environments. It ensures that changes introduced in one release do not degrade performance or behavior in another. When executed consistently, automated tests provide early signals when rendering, loading, or interaction timing begins to drift.

When combined with network‑aware execution, automated browser testing allows teams to observe how performance and functionality behave together, not in isolation. This is critical for applications that rely heavily on client‑side logic, dynamic content loading, or real‑time interactions.

This becomes even more important as richer front‑end frameworks and media‑heavy interfaces become common. On high‑performance networks, even small delays become visible. Automated browser testing helps teams detect these regressions before users do.

Why application performance directly impacts business outcomes

Application performance shapes how users judge a product long before they evaluate features. When performance degrades, users rarely attribute the problem to the network or temporary conditions. They associate it with the product itself.

What users notice first

Slow page loads or delayed responses

Inconsistent behavior across sessions or locations

Visible lag during key actions like login, search, or checkout

These issues are interpreted as signs of poor reliability, not isolated technical faults.

Why tolerance is shrinking

As connectivity improves, users expect applications to keep pace with network capability. Faster networks remove excuses for delays. When performance falls short, users disengage quickly, abandon workflows, or move to alternatives that feel more responsive.

How this affects the business

Performance issues have direct and measurable impact:

Lower conversion rates and shorter sessions

Reduced retention and repeat usage

Declining customer satisfaction and trust

In enterprise settings, increased renewal risk and hesitation around scale

Conclusion

Next‑gen connectivity does more than improve networks. It reshapes user expectations and exposes weaknesses in application performance strategies. Telco testing and automated browser testing are no longer optional for teams building applications in this environment.

Platforms like HeadSpin help bridge the gap between evolving network capabilities and real user experience. By validating performance under real conditions, teams can deliver applications that feel consistent, responsive, and reliable, even as connectivity standards continue to rise.

Media Contact
Company Name: Headspin
Email:Send Email
City: Riverside
Country: United States
Website: https://www.headspin.io/

HER2-Negative Metastatic Breast Cancer Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes | Genentech, AstraZeneca, Merck Sharp & Dohme LLC, Gilead Sciences, BeiGene, Eisai

The Key HER2-Negative Metastatic Breast Cancer Companies in the market include - Genentech, Inc., AstraZeneca, Merck Sharp & Dohme LLC, Gilead Sciences, BeiGene, Eisai Inc., Novartis Pharmaceuticals, Adagene Inc, Jiangsu HengRui Medicine Co., Ltd, Pfizer, Novartis, CytomX Therapeutics, Tyme, Inc, Puma Biotechnology, Inc., G1 Therapeutics, Inc., Context Therapeutics Inc., and others.

DelveInsight’s “HER2-Negative Metastatic Breast Cancer Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the HER2-Negative Metastatic Breast Cancer, historical and forecasted epidemiology as well as the HER2-Negative Metastatic Breast Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the HER2-Negative Metastatic Breast Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; HER2-Negative Metastatic Breast Cancer Market Forecast

Some of the key facts of the HER2-Negative Metastatic Breast Cancer Market Report:

The HER2-Negative Metastatic Breast Cancer market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
In January 2025, Genentech Therapeutics' Phase III clinical trial of Itovebi achieved the key oncology benchmark of improved overall survival (OS) in patients with certain forms of metastatic breast cancer, while also delaying disease progression. Additional findings from the randomized, double-blind study (NCT04191499) revealed that Itovebi, also known as inavolisib, demonstrated a statistically significant and clinically meaningful improvement in OS when combined with Ibrance (palbociclib) and Faslodex (fulvestrant). This benefit was specifically observed in patients with PIK3CA-mutated, hormone receptor (HR)-positive, and HER2-Negative Metastatic Breast Cancer.
The US experienced 253,465 new instances of breast cancer in 2020, according to the Global Cancer Observatory (2020)
According to data from Surveillance, Epidemiology and End Results (SEER, n.d.), the US female population experiences the diagnosis of more than 200,000 new instances of breast cancer each year
According to the Global Cancer Observatory (2020), there were 69,697 new cases of breast cancer in Germany, France, Italy, Spain, and the United Kingdom, respectively, in 2020
Key HER2-Negative Metastatic Breast Cancer Companies: Genentech, Inc., AstraZeneca, Merck Sharp & Dohme LLC, Gilead Sciences, BeiGene, Eisai Inc., Novartis Pharmaceuticals, Adagene Inc, Jiangsu HengRui Medicine Co., Ltd, Pfizer, Novartis, CytomX Therapeutics, Tyme, Inc, Puma Biotechnology, Inc., G1 Therapeutics, Inc., Context Therapeutics Inc., and others
Key HER2-Negative Metastatic Breast Cancer Therapies: Paclitaxel, Doxorubicin, AZD9833, Pembrolizumab, TF2 - 68 Ga-IMP-288, BGB-290, Eribulin, Dapagliflozin, ADG106, Famitinib Malate, Talazoparib Tosylate, Letrozole, CX-2009, SM-88, Neratinib, G1T38, Onapristone, and others
The HER2-Negative Metastatic Breast Cancer epidemiology based on gender analyzed that HER2-Negative Metastatic Breast Cancer mainly develops in older women
The HER2-Negative Metastatic Breast Cancer market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage HER2-Negative Metastatic Breast Cancer pipeline products will significantly revolutionize the HER2-Negative Metastatic Breast Cancer market dynamics.

HER2-Negative Metastatic Breast Cancer Overview

HER2-Negative Metastatic Breast Cancer is a type of breast cancer that has spread beyond the breast and nearby lymph nodes to other parts of the body (metastatic) and does not overexpress the human epidermal growth factor receptor 2 (HER2) protein. Since HER2 is not overactive, HER2-targeted therapies like trastuzumab are ineffective. Treatment typically focuses on hormonal therapy, chemotherapy, or immunotherapy, depending on hormone receptor status (HR-positive or triple-negative). HER2-negative status influences prognosis and treatment strategy.

Get a Free sample for the HER2-Negative Metastatic Breast Cancer Market Report

https://www.delveinsight.com/report-store/her2-negative-metastatic-breast-cancer-market

HER2-Negative Metastatic Breast Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

HER2-Negative Metastatic Breast Cancer Epidemiology Segmentation:

The HER2-Negative Metastatic Breast Cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of HER2-Negative Metastatic Breast Cancer
Prevalent Cases of HER2-Negative Metastatic Breast Cancer by severity
Gender-specific Prevalence of HER2-Negative Metastatic Breast Cancer
Diagnosed Cases of Episodic and Chronic HER2-Negative Metastatic Breast Cancer

Download the report to understand which factors are driving HER2-Negative Metastatic Breast Cancer epidemiology trends @ HER2-Negative Metastatic Breast Cancer Epidemiology Forecast

HER2-Negative Metastatic Breast Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the HER2-Negative Metastatic Breast Cancer market or expected to get launched during the study period. The analysis covers HER2-Negative Metastatic Breast Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the HER2-Negative Metastatic Breast Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

HER2-Negative Metastatic Breast Cancer Therapies and Key Companies

Paclitaxel: Dana-Farber Cancer Institute
Doxorubicin: Genentech, Inc.
AZD9833: AstraZeneca
Pembrolizumab: Merck Sharp & Dohme LLC
TF2 - 68 Ga-IMP-288: Gilead Sciences
BGB-290: BeiGene
Eribulin: Eisai Inc.
Dapagliflozin: Novartis Pharmaceuticals
ADG106: Adagene Inc
Famitinib Malate: Jiangsu HengRui Medicine Co., Ltd
Talazoparib Tosylate: Pfizer
Letrozole: Novartis
CX-2009: CytomX Therapeutics
SM-88: Tyme, Inc
Neratinib: Puma Biotechnology, Inc.
G1T38: G1 Therapeutics, Inc.
Onapristone: Context Therapeutics Inc.

Discover more about therapies set to grab major HER2-Negative Metastatic Breast Cancer market share @ HER2-Negative Metastatic Breast Cancer Treatment Market

Scope of the HER2-Negative Metastatic Breast Cancer Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key HER2-Negative Metastatic Breast Cancer Companies: Genentech, Inc., AstraZeneca, Merck Sharp & Dohme LLC, Gilead Sciences, BeiGene, Eisai Inc., Novartis Pharmaceuticals, Adagene Inc, Jiangsu HengRui Medicine Co., Ltd, Pfizer, Novartis, CytomX Therapeutics, Tyme, Inc, Puma Biotechnology, Inc., G1 Therapeutics, Inc., Context Therapeutics Inc., and others
Key HER2-Negative Metastatic Breast Cancer Therapies: Paclitaxel, Doxorubicin, AZD9833, Pembrolizumab, TF2 - 68 Ga-IMP-288, BGB-290, Eribulin, Dapagliflozin, ADG106, Famitinib Malate, Talazoparib Tosylate, Letrozole, CX-2009, SM-88, Neratinib, G1T38, Onapristone, and others
HER2-Negative Metastatic Breast Cancer Therapeutic Assessment: HER2-Negative Metastatic Breast Cancer current marketed and HER2-Negative Metastatic Breast Cancer emerging therapies
HER2-Negative Metastatic Breast Cancer Market Dynamics: HER2-Negative Metastatic Breast Cancer market drivers and HER2-Negative Metastatic Breast Cancer market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
HER2-Negative Metastatic Breast Cancer Unmet Needs, KOL’s views, Analyst’s views, HER2-Negative Metastatic Breast Cancer Market Access and Reimbursement

To know more about HER2-Negative Metastatic Breast Cancer companies working in the treatment market, visit @ HER2-Negative Metastatic Breast Cancer Clinical Trials and Therapeutic Assessment

Table of Contents

1. HER2-Negative Metastatic Breast Cancer Market Report Introduction

2. Executive Summary for HER2-Negative Metastatic Breast Cancer

3. SWOT analysis of HER2-Negative Metastatic Breast Cancer

4. HER2-Negative Metastatic Breast Cancer Patient Share (%) Overview at a Glance

5. HER2-Negative Metastatic Breast Cancer Market Overview at a Glance

6. HER2-Negative Metastatic Breast Cancer Disease Background and Overview

7. HER2-Negative Metastatic Breast Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of HER2-Negative Metastatic Breast Cancer

9. HER2-Negative Metastatic Breast Cancer Current Treatment and Medical Practices

10. HER2-Negative Metastatic Breast Cancer Unmet Needs

11. HER2-Negative Metastatic Breast Cancer Emerging Therapies

12. HER2-Negative Metastatic Breast Cancer Market Outlook

13. Country-Wise HER2-Negative Metastatic Breast Cancer Market Analysis (2020–2034)

14. HER2-Negative Metastatic Breast Cancer Market Access and Reimbursement of Therapies

15. HER2-Negative Metastatic Breast Cancer Market Drivers

16. HER2-Negative Metastatic Breast Cancer Market Barriers

17. HER2-Negative Metastatic Breast Cancer Appendix

18. HER2-Negative Metastatic Breast Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Knee Osteoarthritis Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observe | Sanofi, Anterogen, Enlivex Therapeutics, ICM, Peptinov, Techfields Pharma, Paradigm Biopharma

The Key Knee Osteoarthritis Companies in the market include - Sanofi, Anterogen, Enlivex Therapeutics, ICM, Sao Thai Duong Joint Stock Company, Peptinov, Techfields Pharma, Taiwan Liposome Company, Centrexion Therapeutics, Biosplice Therapeutic, Noven Pharmaceuticals, Kolon TissueGene, Paradigm Biopharmaceuticals, Organogenesis, BioSenic (Bone Therapeutics), Sorrento Therapeutics, Inc., ICM Biotech Australia, Grünenthal GmbH, Akan Biosciences, LLC, GlaxoSmithKline, and others.

DelveInsight’s “Knee Osteoarthritis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Knee Osteoarthritis, historical and forecasted epidemiology as well as the Knee Osteoarthritis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Knee Osteoarthritis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Knee Osteoarthritis Market Forecast

Some of the key facts of the Knee Osteoarthritis Market Report:

The Knee Osteoarthritis market size was valued ~USD 14, 400 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034).
In January 2026, Biosplice Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-class therapies through small-molecule inhibition of CLK/DYRK kinases, announced the submission of a New Drug Application (NDA) to the U.S. FDA for its investigational knee osteoarthritis treatment. The company’s lead candidate, lorecivivint (LOR), is a small-molecule injectable suspension designed for intra-articular administration once or twice annually. Evaluated across 11 clinical studies, LOR demonstrated meaningful improvements in pain and physical function while maintaining a favorable safety profile. Findings from the Phase 3 OA-07 trial further showed sustained improvements in medial joint space width on imaging over multiple years, supporting LOR’s potential to become the first disease-modifying therapy for osteoarthritis.
In May 2025, Lipogems announced the successful completion of its ARISE I U.S. FDA IDE Study, with the final patient visit now concluded. This marks a significant milestone in progressing Lipogems as a treatment option for knee osteoarthritis (OA) in patients who are not eligible for or ready to undergo knee replacement. The double-blind, randomized controlled trial included 173 participants across 18 leading U.S. clinical sites. The study's primary focus is on assessing pain relief and functional improvement 12 months after injection. Results on efficacy and safety are anticipated by late 2025.
In May 2025, Genascence Corporation, a clinical-stage biotech firm focused on transforming musculoskeletal disease treatment through gene therapy, reported positive 12-month safety and biomarker findings from its Phase 1b DONATELLO trial of GNSC-001. This investigational gene therapy targets interleukin 1 (IL-1) for treating knee osteoarthritis (OA). The 12-month results confirmed the trial met its primary endpoint, showing consistent safety and tolerability across all tested doses. Additionally, the study met a key secondary endpoint, demonstrating sustained IL-1Ra expression in synovial fluid, reinforcing the six-month data previously reported.
In May 2025, Moximed, a pioneering medical device company focused on enhancing care for individuals with knee osteoarthritis (OA), announced that the first patients have been treated in its latest randomized controlled trial (RCT). The MOTION study is a prospective, multicenter trial designed to compare the effectiveness of the MISHA Knee System against non-surgical treatment options in patients with medial knee osteoarthritis.
In April 2025, Pacira BioSciences reported that its gene therapy candidate, PCRX-201 (enekinragene inzadenovec), showed long-lasting improvements in knee pain, mobility, and stiffness for up to two years in a Phase I trial. Participants received a single local injection of the therapy. The study included 72 individuals aged 30 to 80, categorized based on the severity of their knee osteoarthritis using the Kellgren-Lawrence (K/L) grading system.
In April 2025, Israel-based Enlivex Therapeutics announced the completion of enrollment for the Phase II portion of its Phase I/II trial evaluating Allocetra, an off-the-shelf cell therapy for moderate to severe knee osteoarthritis. In this phase, over 133 subjects were randomized and treated. The multi-center, randomized trial is divided into two stages, with Phase I being an open-label, dose-escalation study focused on assessing the safety and tolerability of Allocetra injections into the knee.
In March 2025, RION, a clinical-stage company specializing in regenerative medicine and exosome-based therapies, announced the enrollment of the first patient in its Phase 1b trial of Purified Exosome Product™ (PEP™) for treating Knee Osteoarthritis (OA). This marks a significant step in RION’s mission to develop cutting-edge regenerative solutions for unmet medical needs.
In September 2024, Cytonics announced the completion of patient enrollment in a Phase I clinical trial for CYT-108, which is being investigated as a potential disease-modifying therapy for knee osteoarthritis (OA). CYT-108 is a recombinant variant of the alpha-2-macroglobulin blood serum protease inhibitor.
Among the 7MM, the US holds the largest market size for knee osteoarthritis (OA). This growth is driven by the emergence of new therapies, with the market size for knee OA estimated to be around USD 8,900 million in 2023.
In May 2024, Organogenesis reported encouraging topline results from a Phase III randomized controlled trial assessing the safety and effectiveness of ReNu in managing symptoms of knee osteoarthritis.
In 2023, the US recorded the highest number of prevalent cases, totaling approximately 18,499,200, followed by Japan.
In the US, the age group of 70 years and older represented the highest number of cases in 2023, while the lowest number of cases was observed in the 18–39 age group.
A study by Yokota et al. (2023) indicates that knee osteoarthritis is highly prevalent in Japan, affecting an estimated 25.3 million individuals over the age of 40, with around 8 million experiencing symptomatic cases.
In 2023, there were approximately 97 million diagnosed cases of knee osteoarthritis in the 7MM. This number is expected to rise during the forecast period from 2024 to 2034.
In 2023, within the EU4 and the UK, the highest proportion of age-specific knee osteoarthritis cases were observed in individuals aged 70 and above, followed by those in the 60-69 and 50-59 age groups.
Key Knee Osteoarthritis Companies: Sanofi, Anterogen, Enlivex Therapeutics, ICM, Sao Thai Duong Joint Stock Company, Peptinov, Techfields Pharma, Taiwan Liposome Company, Centrexion Therapeutics, Biosplice Therapeutic, Noven Pharmaceuticals, Kolon TissueGene, Paradigm Biopharmaceuticals, Organogenesis, BioSenic (Bone Therapeutics), Sorrento Therapeutics, Inc., ICM Biotech Australia, Grünenthal GmbH, Akan Biosciences, LLC, GlaxoSmithKline, and others
Key Knee Osteoarthritis Therapies: SAR446959, ANT-301, Allocetra, ICM-203, TD0015, PPV06, X0002, TLC599, CNTX-4975, Lorecivivint (SM04690), HP-5000, Invossa (TG-C), ZILOSUL (pentosan polysulfate sodium), ReNu (Amniotic Suspension Allograft), JTA-004, Resiniferatoxin, ICM-203, RTX-GRT7039, StroMel, GSK3858279, and others
The Knee Osteoarthritis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Knee Osteoarthritis pipeline products will significantly revolutionize the Knee Osteoarthritis market dynamics.

Knee Osteoarthritis Overview

Knee osteoarthritis (OA) is a degenerative joint disease where the cartilage in the knee deteriorates over time, causing pain, stiffness, swelling, and reduced mobility. It is commonly associated with aging, injury, or overuse, leading to the wear and tear of the knee joint. Symptoms can range from mild discomfort to severe disability, often affecting daily activities.

Get a Free sample for the Knee Osteoarthritis Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/knee-osteoarthritis-market

Knee Osteoarthritis Epidemiology

Knee Osteoarthritis Epidemiology Segmentation:

The Knee Osteoarthritis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Knee Osteoarthritis
Prevalent Cases of Knee Osteoarthritis by severity
Gender-specific Prevalence of Knee Osteoarthritis
Diagnosed Cases of Episodic and Chronic Knee Osteoarthritis

Download the report to understand which factors are driving Knee Osteoarthritis epidemiology trends @ Knee Osteoarthritis Epidemiology Forecast

Knee Osteoarthritis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Knee Osteoarthritis market or expected to get launched during the study period. The analysis covers Knee Osteoarthritis market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Knee Osteoarthritis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Knee Osteoarthritis Therapies and Key Companies

SAR446959: Sanofi
ANT-301: Anterogen
Allocetra: Enlivex Therapeutics
ICM-203: ICM
TD0015: Sao Thai Duong Joint Stock Company
PPV06: Peptinov
X0002: Techfields Pharma
TLC599: Taiwan Liposome Company
CNTX-4975: Centrexion Therapeutics
Lorecivivint (SM04690): Biosplice Therapeutic
HP-5000: Noven Pharmaceuticals
Invossa (TG-C): Kolon TissueGene
ZILOSUL (pentosan polysulfate sodium): Paradigm Biopharmaceuticals
ReNu (Amniotic Suspension Allograft): Organogenesis
JTA-004: BioSenic (Bone Therapeutics)
Resiniferatoxin: Sorrento Therapeutics, Inc.
ICM-203: ICM Biotech Australia
RTX-GRT7039: Grünenthal GmbH
StroMel: Akan Biosciences, LLC
GSK3858279: GlaxoSmithKline

Discover more about therapies set to grab major Knee Osteoarthritis market share @ Knee Osteoarthritis Treatment Landscape

Knee Osteoarthritis Market Strengths

New approaches to osteoarthritis therapy currently being investigated include attempts to identify disease-modifying osteoarthritis drugs, tissue engineering for reconstituting intact cartilage and joint tissues, and biomechanically active methods for reducing aberrant loading in osteoarthritis-involved joints.
Single injection joint function enhancing hyaluronic acid formulation’s sales are steadily rising, and companies are looking to expand into new markets to increase their single injection product profit.

Knee Osteoarthritis Market Opportunities

Disease-modifying osteoarthritis drugs (DMOADs) could offer new therapeutic targets to restore the quality and function of tissues affected by osteoarthritis.
People eagerly await non-opioid options, and key players can target this lucrative market segment while others are developing therapies for the same.

Scope of the Knee Osteoarthritis Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Knee Osteoarthritis Companies: Sanofi, Anterogen, Enlivex Therapeutics, ICM, Sao Thai Duong Joint Stock Company, Peptinov, Techfields Pharma, Taiwan Liposome Company, Centrexion Therapeutics, Biosplice Therapeutic, Noven Pharmaceuticals, Kolon TissueGene, Paradigm Biopharmaceuticals, Organogenesis, BioSenic (Bone Therapeutics), Sorrento Therapeutics, Inc., ICM Biotech Australia, Grünenthal GmbH, Akan Biosciences, LLC, GlaxoSmithKline, and others
Key Knee Osteoarthritis Therapies: SAR446959, ANT-301, Allocetra, ICM-203, TD0015, PPV06, X0002, TLC599, CNTX-4975, Lorecivivint (SM04690), HP-5000, Invossa (TG-C), ZILOSUL (pentosan polysulfate sodium), ReNu (Amniotic Suspension Allograft), JTA-004, Resiniferatoxin, ICM-203, RTX-GRT7039, StroMel, GSK3858279, and others
Knee Osteoarthritis Therapeutic Assessment: Knee Osteoarthritis current marketed and Knee Osteoarthritis emerging therapies
Knee Osteoarthritis Market Dynamics: Knee Osteoarthritis market drivers and Knee Osteoarthritis market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Knee Osteoarthritis Unmet Needs, KOL’s views, Analyst’s views, Knee Osteoarthritis Market Access and Reimbursement

To know more about Knee Osteoarthritis companies working in the treatment market, visit @ Knee Osteoarthritis Clinical Trials and Therapeutic Assessment

Table of Contents

1. Knee Osteoarthritis Market Report Introduction

2. Executive Summary for Knee Osteoarthritis

3. SWOT analysis of Knee Osteoarthritis

4. Knee Osteoarthritis Patient Share (%) Overview at a Glance

5. Knee Osteoarthritis Market Overview at a Glance

6. Knee Osteoarthritis Disease Background and Overview

7. Knee Osteoarthritis Epidemiology and Patient Population

8. Country-Specific Patient Population of Knee Osteoarthritis

9. Knee Osteoarthritis Current Treatment and Medical Practices

10. Knee Osteoarthritis Unmet Needs

11. Knee Osteoarthritis Emerging Therapies

12. Knee Osteoarthritis Market Outlook

13. Country-Wise Knee Osteoarthritis Market Analysis (2020–2034)

14. Knee Osteoarthritis Market Access and Reimbursement of Therapies

15. Knee Osteoarthritis Market Drivers

16. Knee Osteoarthritis Market Barriers

17. Knee Osteoarthritis Appendix

18. Knee Osteoarthritis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Graves Ophthalmopathy Market Growth to Surge During Forecast Period (2024–2034), Says DelveInsight | Novartis, AdvanceCor, Apitope, Worg Pharma, AV7 Limited

The Key Graves Ophthalmopathy Companies in the market include - Immunovant Sciences GmbH, Horizon Pharma USA, Inc., Viridian Therapeutics, Inc., Tourmaline Bio, Inc., ACELYRIN Inc., Hoffmann-La Roche, Horizon Therapeutics USA, Inc., Lassen Therapeutics Inc., Novartis, Sling Therapeutics, Inc., Lassen Therapeutics, and others

The Graves Ophthalmopathy market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Graves Ophthalmopathy pipeline products will significantly revolutionize the Graves Ophthalmopathy market dynamics.

DelveInsight’s “Graves Ophthalmopathy Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Graves Ophthalmopathy, historical and forecasted epidemiology as well as the Graves Ophthalmopathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Graves Ophthalmopathy market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Get a Free sample for the Graves Ophthalmopathy Market Report -

https://www.delveinsight.com/report-store/graves-ophthalmopathy-market

Some of the key facts of the Graves Ophthalmopathy Market Report:

The Graves Ophthalmopathy market size was valued approximately USD 2600 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In May 2025, Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company dedicated to developing and commercializing potential best-in-class treatments for serious and rare conditions, has announced encouraging long-term durability results from the Phase 3 THRIVE clinical trial of veligrotug (“veli”). Veli is an intravenously administered antibody targeting the insulin-like growth factor-1 receptor (IGF-1R) and is being evaluated in patients with active thyroid eye disease (TED), an autoimmune disorder marked by inflammation, tissue expansion, and damage around and behind the eyes.
In January 2025, Sling Therapeutics, Inc., a late-stage biopharmaceutical company specializing in the development of oral therapies for thyroid eye disease (TED), has announced topline efficacy and safety results from its Phase 2b/3 LIDS trial evaluating linsitinib in patients with active, moderate to severe TED. Linsitinib, the company’s lead oral small molecule candidate, is administered twice daily and is currently in clinical development for TED. It targets the well-established IGF-1R pathway and has demonstrated a favorable safety profile, having been studied in over 900 patients across fifteen clinical trials in various therapeutic areas.
In September 2024, Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company dedicated to discovering and developing potential best-in-class treatments for serious and rare diseases, today announced promising topline results from the THRIVE phase 3 clinical trial of VRDN-001, now known as veligrotug. This intravenously administered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody is being evaluated in patients with active thyroid eye disease (TED), an autoimmune disorder marked by inflammation, growth, and damage to the tissues surrounding and behind the eyes
In 2022, approximately 2,385,900 cases of Graves Ophthalmopathy were reported in the seven major markets (7MM), and it is anticipated that these figures will rise throughout the study period from 2020 to 2034.
In 2022, it was estimated that there were approximately 448,800 diagnosed prevalent cases of Graves Ophthalmopathy in the United States. It is projected that these cases will increase over the study period from 2020 to 2034.
In 2022, Germany had the highest number of diagnosed prevalent cases of Graves Ophthalmopathy patients among the EU4 and the UK, with around 105,900 cases. Conversely, Spain had the fewest cases, with approximately 59,200 cases in 2022.
In the United States, the number of diagnosed prevalent cases of Graves Ophthalmopathy was higher among females compared to males in 2022, with approximately 89,800 cases in males and around 359,000 cases in females.
Key Graves Ophthalmopathy Companies: Immunovant Sciences GmbH, Horizon Pharma USA, Inc., Viridian Therapeutics, Inc., Tourmaline Bio, Inc., ACELYRIN Inc., Hoffmann-La Roche, Horizon Therapeutics USA, Inc., Lassen Therapeutics Inc., Novartis, Sling Therapeutics, Inc., Lassen Therapeutics, and others
Key Graves Ophthalmopathy Therapies: Batoclimab (IMVT 1401), RVT-1401, Teprotumumab, VRDN-001 10 mg/kg Drug, TOUR006 - 20 MG, IBI311, lonigutamab, Satralizumab, TEPEZZA, LASN01, CFZ533, linsitinib, LASN01, and others
The Graves Ophthalmopathy epidemiology based on gender analyzed that the females are affected more as compared to males in the case of Graves Ophthalmopathy

Graves Ophthalmopathy Overview

Graves' ophthalmopathy, also known as thyroid eye disease or Graves' orbitopathy, is a condition characterized by inflammation and swelling of the tissues surrounding the eyes. It is commonly associated with Graves' disease, an autoimmune disorder that affects the thyroid gland, leading to hyperthyroidism (overactive thyroid).

To Know in detail about the Graves Ophthalmopathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Graves Ophthalmopathy Market Forecast

Graves Ophthalmopathy Market

The dynamics of the Graves Ophthalmopathy market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.

“The DAVIAD project successfully resulted in the manufacture GMP grade ATX-GD-59 and completion of pharmacodynamic and toxicology studies in order to progress the therapeutic vaccine into a Phase I/IIa clinical trial. In the clinical trial, the vaccine was proven to be safe and well tolerated.”

Graves Ophthalmopathy Epidemiology

Graves Ophthalmopathy Epidemiology Segmentation:

The Graves Ophthalmopathy market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Prevalent Cases of Graves Ophthalmopathy in the 7MM
Diagnosed Prevalent Cases of Graves Ophthalmopathy in the 7MM
Gender-specific Diagnosed Prevalent Cases of Graves Ophthalmopathy in the 7MM
Moderate-to-severe Drug-treated Cases of Acute Graves Ophthalmopathy in the 7MM
Acute Diagnosed Prevalent Cases of Graves Ophthalmopathy in the 7MM
Diagnosed Prevalent Cases of Graves Ophthalmopathy by Chronicity in the 7MM

Download the report to understand which factors are driving Graves Ophthalmopathy epidemiology trends @ Graves Ophthalmopathy Epidemiological Insights

Graves Ophthalmopathy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Graves Ophthalmopathy market or expected to get launched during the study period. The analysis covers Graves Ophthalmopathy market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Graves Ophthalmopathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Graves Ophthalmopathy Therapies and Key Companies

Batoclimab (IMVT 1401): Immunovant Sciences
RVT-1401: Immunovant Sciences GmbH
Teprotumumab: Horizon Pharma USA, Inc.
VRDN-001 10 mg/kg Drug: Viridian Therapeutics, Inc.
Batoclimab: Immunovant Sciences GmbH
TOUR006 - 20 MG: Tourmaline Bio, Inc.
IBI311: Innovent Biologics (Suzhou) Co. Ltd.
lonigutamab: ACELYRIN Inc.
Satralizumab: Hoffmann-La Roche
TEPEZZA: Horizon Therapeutics USA, Inc.
LASN01: Lassen Therapeutics Inc.
CFZ533: Novartis
linsitinib: Sling Therapeutics, Inc.
LASN01: Lassen Therapeutics

To know more about Graves Ophthalmopathy treatment, visit @ Graves Ophthalmopathy Medications

Graves Ophthalmopathy Market Strengths

The recent US FDA approval of Horizon’s TEPEZZA has accelerated the research and development of GO.
Recent efforts to increase patient and clinician awareness of GO, with various awareness campaigns, are expected to increase early diagnosis and treatment of GO.

Graves Ophthalmopathy Market opportunities

Designing an effective molecule with an intended delivery mode that is matched to the intended target compartment is a necessary first step in ocular drug discovery programs.
Lack of availability of disease-modifying treatment for chronic patients, who have a significant impact on their emotional and social well-being.

Scope of the Graves Ophthalmopathy Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Graves Ophthalmopathy Companies: Novartis, AdvanceCor, Apitope, Worg Pharmaceuticals, AV7 Limited, and others
Key Graves Ophthalmopathy Therapies: Batoclimab (IMVT 1401), RVT-1401, Teprotumumab, VRDN-001 10 mg/kg Drug, TOUR006 - 20 MG, IBI311, lonigutamab, Satralizumab, TEPEZZA, LASN01, CFZ533, linsitinib, LASN01, and others
Graves Ophthalmopathy Therapeutic Assessment: Graves Ophthalmopathy current marketed and Graves Ophthalmopathy emerging therapies
Graves Ophthalmopathy Market Dynamics: Graves Ophthalmopathy market drivers and Graves Ophthalmopathy market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Graves Ophthalmopathy Unmet Needs, KOL’s views, Analyst’s views, Graves Ophthalmopathy Market Access and Reimbursement

Discover more about therapies set to grab major Graves Ophthalmopathy market share @ Graves Ophthalmopathy Treatment Landscape

Table of Contents

1. Graves Ophthalmopathy Market Report Introduction

2. Executive Summary for Graves Ophthalmopathy

3. SWOT analysis of Graves Ophthalmopathy

4. Graves Ophthalmopathy Patient Share (%) Overview at a Glance

5. Graves Ophthalmopathy Market Overview at a Glance

6. Graves Ophthalmopathy Disease Background and Overview

7. Graves Ophthalmopathy Epidemiology and Patient Population

8. Country-Specific Patient Population of Graves Ophthalmopathy

9. Graves Ophthalmopathy Current Treatment and Medical Practices

10. Graves Ophthalmopathy Unmet Needs

11. Graves Ophthalmopathy Emerging Therapies

12. Graves Ophthalmopathy Market Outlook

13. Country-Wise Graves Ophthalmopathy Market Analysis (2020–2034)

14. Graves Ophthalmopathy Market Access and Reimbursement of Therapies

15. Graves Ophthalmopathy Market Drivers

16. Graves Ophthalmopathy Market Barriers

17. Graves Ophthalmopathy Appendix

18. Graves Ophthalmopathy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaura Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Neurotrophic Keratitis Market to Witness Promising Upswing by 2034, DelveInsight Forecasts | Oyster Point Pharma, Recordati Rare Diseases, MimeTech, Claris Biotherapeutics, ReGenTree, BRIM Biotech

The Key Neurotrophic Keratitis Companies in the market include - Dompé Farmaceutici, BRIM Biotechnology, ReGenTree, LLC, Oyster Point Pharma, Inc., Syneos Health, Recordati Rare Diseases, MimeTech, Claris Biotherapeutics, and others.

DelveInsight’s “Neurotrophic Keratitis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Neurotrophic Keratitis, historical and forecasted epidemiology as well as the Neurotrophic Keratitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The Neurotrophic Keratitis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Neurotrophic Keratitis pipeline products will significantly revolutionize the Neurotrophic Keratitis market dynamics.

Get a Free sample for the Neurotrophic Keratitis Market Report:

https://www.delveinsight.com/report-store/neurotrophic-keratitis-market

Some of the key facts of the Neurotrophic Keratitis Market Report:

The Neurotrophic Keratopathy market size was valued at approximately USD 870 million in 2024 and is expected to expand at a notable CAGR throughout the study period from 2020 to 2034.
In April 2025, OKYO Pharma confirmed that urcosimod, previously known as OK-101, maintains stability for over two and a half years in single-use ampoules designed for patient use. This achievement marks a significant advancement in supporting the drug’s long-term potential as it moves through clinical development. Urcosimod is currently undergoing a Phase 2b clinical trial a randomized, placebo-controlled, double-masked study with 48 participants—aimed at evaluating its efficacy in treating neurotrophic keratopathy (NCP), a severe and progressive degenerative eye condition.
In January 2025, Provectus Biopharmaceuticals, Inc. (“Provectus”) (OTCQB: PVCT) announced the successful completion of a $3 million seed funding round for VisiRose, Inc., its subsidiary focused on developing innovative ocular therapies. The funding supports preparations for a pre-investigational new drug (IND) meeting with the U.S. Food and Drug Administration (FDA) regarding RB-PDAT, a potential treatment for infectious keratitis.
In 2024, the United States dominated the neurotrophic keratitis market, accounting for approximately 98% of the total market size across the 7MM, far exceeding the contributions from the EU4 countries, the United Kingdom, and Japan.
In 2024, France held the largest share of the neurotrophic keratitis market across the EU4 and the UK, accounting for nearly 30%, while Germany recorded the smallest share at around 10% during the same year.
The expected launch of new therapies, such as BRM424, is likely to reshape the neurotrophic keratitis market and influence its overall size in the years ahead.
In 2024, approximately 60,300 individuals across the EU4 and the UK were living with neurotrophic keratitis, underscoring a substantial regional disease burden and the increasing need for earlier diagnosis, better treatment options, and targeted approaches to prevent long-term corneal damage.
Within the EU4 and the UK, the United Kingdom reported the highest number of diagnosed prevalent neurotrophic keratitis cases at approximately 8,500 in 2024, followed by Germany with around 6,000 cases, while Spain recorded the lowest prevalence at about 3,400 cases.
In 2024, diagnosed prevalent neurotrophic keratitis cases in the United States exhibited a notable gender disparity, with approximately 20,000 cases reported in females compared to about 13,500 cases in males, indicating a higher disease burden among women.
In 2024, Japan recorded approximately 12,350 prevalent cases of neurotrophic keratitis, and this figure is projected to increase further by 2034, indicating a rising disease burden.
In 2024, neurotrophic keratitis cases in Japan were largely concentrated in Stage 3 disease, characterized by corneal ulcers, with approximately 2,500 cases. This was followed by Stage 2 persistent epithelial defects at around 1,950 cases and Stage 1 epithelial alterations at about 1,110 cases. The distribution reflects a higher burden of advanced disease and emphasizes the importance of early diagnosis and timely treatment to limit disease progression.
Key Neurotrophic Keratitis Companies: Dompé Farmaceutici, BRIM Biotechnology, ReGenTree, LLC, Oyster Point Pharma, Inc., Syneos Health, Recordati Rare Diseases, MimeTech, Claris Biotherapeutics, and others
Key Neurotrophic Keratitis Therapies: OXERVATE (Cenegermin-bkbj), BRM424, RGN-259, OC-01 (varenicline), cenegermin-bkbj, Udonitrectag, rhNGF, REC 0559, CSB-001, and others
The Neurotrophic Keratitis epidemiology based on gender analyzed that most of the Neurotrophic Keratitis cases comprise of the female population
The Neurotrophic Keratitis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Neurotrophic Keratitis pipeline products will significantly revolutionize the Neurotrophic Keratitis market dynamics.

To Know in detail about the Neurotrophic Keratitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Neurotrophic Keratitis Market Forecast

Neurotrophic Keratitis Epidemiology

Neurotrophic Keratitis Epidemiology Segmentation:

The Neurotrophic Keratitis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Neurotrophic Keratitis
Prevalent Cases of Neurotrophic Keratitis by severity
Gender-specific Prevalence of Neurotrophic Keratitis
Diagnosed Cases of Episodic and Chronic Neurotrophic Keratitis

Download the report to understand which factors are driving Neurotrophic Keratitis epidemiology trends @ Neurotrophic Keratitis Epidemiology Forecast

Neurotrophic Keratitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Neurotrophic Keratitis market or expected to get launched during the study period. The analysis covers Neurotrophic Keratitis market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Neurotrophic Keratitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Neurotrophic Keratitis Therapies and Key Companies

OXERVATE (Cenegermin-bkbj): Dompé Farmaceutici
BRM424: BRIM Biotechnology
RGN-259: ReGenTree, LLC
OC-01 (varenicline): Oyster Point Pharma, Inc.
cenegermin-bkbj: Dompé Farmaceutici
Udonitrectag: Syneos Health
rhNGF: Dompé Farmaceutici
REC 0559: Recordati Rare Diseases/MimeTech
CSB-001: Claris Biotherapeutics

Discover more about therapies set to grab major Neurotrophic Keratitis market share @ Neurotrophic Keratitis Treatment Market

Neurotrophic Keratitis Market Strengths

Increasing prevalence of other conditions causes neurotrophic keratitis, thereby increasing NK population.
The development of novel molecules potentially targets epithelial healing and corneal innervation.
Advances in biotechnology, laser and robotic treatment also aid in the treatment of Neurotrophic Keratitis.

Neurotrophic Keratitis Market Opportunities

The recent approval of Oxervate by EMA and priority review designation approved by the USFDA will popularize the utilization of recombinant human nerve growth factors for the treatment of neurotrophic keratitis during the forecast period.
Researchers are increasing their investments to develop and discover drugs that could potentially treat rare eye disease

Scope of the Neurotrophic Keratitis Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Neurotrophic Keratitis Companies: Dompé Farmaceutici, BRIM Biotechnology, ReGenTree, LLC, Oyster Point Pharma, Inc., Syneos Health, Recordati Rare Diseases, MimeTech, Claris Biotherapeutics, and others
Key Neurotrophic Keratitis Therapies: OXERVATE (Cenegermin-bkbj), BRM424, RGN-259, OC-01 (varenicline), cenegermin-bkbj, Udonitrectag, rhNGF, REC 0559, CSB-001, and others
Neurotrophic Keratitis Therapeutic Assessment: Neurotrophic Keratitis current marketed and Neurotrophic Keratitis emerging therapies
Neurotrophic Keratitis Market Dynamics: Neurotrophic Keratitis market drivers and Neurotrophic Keratitis market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Neurotrophic Keratitis Unmet Needs, KOL’s views, Analyst’s views, Neurotrophic Keratitis Market Access and Reimbursement

To know more about Neurotrophic Keratitis companies working in the treatment market, visit @ Neurotrophic Keratitis Clinical Trials and Therapeutic Assessment

Table of Contents

1. Neurotrophic Keratitis Market Report Introduction

2. Executive Summary for Neurotrophic Keratitis

3. SWOT analysis of Neurotrophic Keratitis

4. Neurotrophic Keratitis Patient Share (%) Overview at a Glance

5. Neurotrophic Keratitis Market Overview at a Glance

6. Neurotrophic Keratitis Disease Background and Overview

7. Neurotrophic Keratitis Epidemiology and Patient Population

8. Country-Specific Patient Population of Neurotrophic Keratitis

9. Neurotrophic Keratitis Current Treatment and Medical Practices

10. Neurotrophic Keratitis Unmet Needs

11. Neurotrophic Keratitis Emerging Therapies

12. Neurotrophic Keratitis Market Outlook

13. Country-Wise Neurotrophic Keratitis Market Analysis (2020–2034)

14. Neurotrophic Keratitis Market Access and Reimbursement of Therapies

15. Neurotrophic Keratitis Market Drivers

16. Neurotrophic Keratitis Market Barriers

17. Neurotrophic Keratitis Appendix

18. Neurotrophic Keratitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.